Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

February 1, 2022

Study Completion Date

July 1, 2022

Conditions
CancerImmune DefectCardiovascular Abnormalities
Interventions
DIAGNOSTIC_TEST

Cardiac MRI

Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy

DEVICE

Smart cloth

A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.

OTHER

Biobanking

Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.

Trial Locations (1)

75015

AP-HP - Hôpital européen Georges-Pompidou, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fédération Française de Cardiologie

OTHER

collaborator

BioSerenity

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04586894 - Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter